Esperion Therapeutics (ESPR) Tops Q3 EPS by 6c

Esperion Therapeutics (NASDAQ: ESPR) reported Q3 EPS of ($0.37), $0.06 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $34 million versus the consensus estimate of $29.59 million.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results
• Vireo Growth completes acquisition of C21 Investments